Faes Farma, S.A. — Cyborg Score 6/10

Strategic Profile

Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth. The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The company's research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome.

Cyborg Score Rationale

Faes Farma demonstrates solid fundamentals as an established 90+ year pharmaceutical company with international presence, diversified portfolio, and recent strategic focus on high-growth areas like ophthalmology. However, the company faces headwinds including recent stock price declines and the challenges of competing in the competitive pharmaceutical sector.

Top Insights

• Ophthalmology is a key growth opportunity with expected double-digit growth
• Pharmaceutical division achieved 9% growth to €269M, with international markets driving 14% growth
• Presence in over 130 countries positions company for global expansion
• Animal nutrition division (FARM Faes) provides diversification beyond human pharma

Named Competitors

• Grifols — Spanish pharmaceutical and diagnostics company
• Roche Pharma — Global pharmaceutical leader
• Novartis — Global diversified pharma company

Recent Developments

• (Feb 2026) Q4 2025 earnings release published
• (Nov 2025) Ophthalmology acquisitions consolidated as transformational strategy milestone
• (Mar 2025) Acquisition of Edol announced to strengthen ophthalmology portfolio

Open the full interactive Faes Farma, S.A. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.